Pharmacotherapy of borderline personality disorder

Borderline Personality Disorder

Volumn , Issue , 2005, Pages 243-257

  Frankenburg, Frances R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35548956837     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. Bender DS, Dolan RT, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, Shea MT, Zanarini MC, Oldham JM, Gunderson JG. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001; 158:295-302.
2. Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J. Treatment histories of borderline inpatients. Compr Psychiatry 2001; 42:144-150.
3. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization of borderline patients and axis II comparison subjects followed prospectively for six years. J Clin Psychiatry. 2004; 65:28-36.
4. Pennes HH. Clinical reactions of schizophrenics to sodium amytal, pervitin hydrochloride, mescaline sulfate, and D-Lysergic acid diethylamide (LSD 25). J Nerv Ment Dis 1954; 119:95-112.
5. Hoch PH, Polatin P. Pseudoneurotic form of schizophrenia. Psychiatr Q 1949; 23:248-276.
6. Vilkin MI. Comparative chemotherapeutic trial in treatment of chronic borderline patients. Am J Psychiatry 1964; 120:1004.
7. Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967; 16:118-126.
8. Hedberg DL, Houck JH, Gluceck B. Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 1971; 127:61-66.
9. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord 1982; 4:291-298.
10. Soloff PH, George A, Nathan RS, Schulz PM, Perel JM. Progress in pharma-cotherapy of borderline disorders. Arch Gen Psychiatry 1986; 43:691-697.
11. Soloff PH, George A, Nathan RS, Schulz PM, Cornelius JR, Herring J, Perel JM. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9:238-246.
12. Soloff PH, George A, Nathan RS, Schulz PM, Perel JM. Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry 1986; 143:1603-1605.
13. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50:377-385.
14. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45:111-119.
15. Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142:98-100.
16. Parsons B, Quitkin FM, McGrath PJ, Steart JW, Tricamo E, Ocepek-Welikson K, Harrison W, Rabkin JG, Wager SG, Nunes E. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psycho-pharmacol Bull 1989; 25:524-534.
17. Zanarini MC, Frankenburg FR, Dubo ED, Sickel AE, Trikha A, Levin A, Reynolds V. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998; 155:1733-1739.
18. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuro-Psychopharmacol Biol Psychiat 1989; 13:885-893.
19. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26:151-154.
20. Gunderson JG, Kolb JE, Austin V. Diagnosing borderline patients with a semi-structured interview. Arch Gen Psychiatry 1981; 138:896-903.
21. Markovitz PJ, Calabrese, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064-1067.
22. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale: preliminary report. Psychopharmacol Bull 1997; 9:13-28.
23. Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31:773-777.
24. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23-29.
25. Endicott J, Sptizer RL, Fliess Jl. The Global Assessment Scale: A process for measuring overall severity of psychiatric disturbance. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976:583-584.
26. Markovitz P. Pharmacotherapy of impulsivity, aggression and related disorders. In: Hollander E, Stein D, eds. Impulsivity and Aggression. West Sussex, England: John Wiley & Sons, 1995:263-287.
27. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159:2048-2054.
28. Healy D. Lines of evidence on the risks of suicide with selective serotonin reup-take inhibitors. Psychother Psychosom 2003; 72:71-79.
29. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 2147:207-210.
30. Jick H, Kaye JA, Jick SS. Antidepressants and risk of suicidal behaviors. J Am Med Assoc 2004; 292:338-343.
31. Baldessarini RJ, Frankenburg FR. Clozapine a novel antipsychotic agent. N Engl J Med 1991; 324:746-754.
32. Frankenburg FR, Zanarini MC. Clozapine treatment in borderline patients: a preliminary study. Compr Psychiatry 1993; 34:402-405.
33. Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL. The revised diagnostic interview for borderlines: discriminating BPD from other axis II disorders. J Personal Disord 1989; 3:10-18.
34. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10:799-812.
35. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59:103-107.
36. Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman JA, Pollack S, Safferman AZ, Kane JM. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994; 55: 78-81.
37. Chengappa KNR, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999; 60:477-484.
38. Parker GF. Clozapine and borderline personality disorder. Psychiatr Serv 2002; 53:348-349.
39. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46:1429-1435.
40. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62:849-854.
41. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65:104-109.
42. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63:241-244.
43. Schulz SC, Camlin KL, Berry S, Friedman L. Risperidone for borderline personality disorder: a double-blind study. 39th Annual Meeting of the American College of Neuropsychopharmacology, Nashville, Tenn, 1999.
44. Akiskal HS, Hirschfeld RMA, Yerevanian BI. The relationship of personality to affective disorders. A Critical Review. Arch Gen Psychiatry 1983; 40: 801-810.
45. Links P, Steiner M, Boiago I, Irwin D. Lithium therapy for borderline patients: preliminary findings. J Personal Disord 1990; 4:173-181.
46. Gardner DL, Cowdry RAW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519-522.
47. Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56: 506-510.
48. Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL, Bernstein DP. Development of neuropharmacologically based assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 1991; 3(suppl):44-51.
49. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995; 7:33-37.
50. Hollander E, Allen A, Lopez RP, Bienstock C, Grossman R, Siever L, Margolin L, Stein D. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62:199-203.
51. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63:442-446.
52. Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000; 20:1S-17S.
53. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51:333-343.
54. Hibbeln JR. Fish consumption and major depression. Lancet 1998; 351:1213.
55. Stoll AL, Severus WE, Freeman MP, Reuter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
56. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003; 160:167-169.
57. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
58. Keck PE Jr, McElroy SL, Freeman MP, Altshuler LL, Frye MA, Kupka R, Nolen W, Grunze H, Walden J, Denicoff KD, Leverich GS, Post RM. Rando-mized, placebo-controlled trial of eicosapentanoic acid in bipolar depression. Bipolar Disord 2003; 5(suppl 1): 58 (abstract P99).
59. Keck PE Jr, McElroy SL, Freeman MP, Altshuler LL, Frye MA, Mintz J, Hwang S, Kupka R, Nolen W, Grunze H, Walden J, Denicoff KD, Leverich GS, Post RM. Randomized, placebo-controlled trial of eicosapentanoic acid in rapid cycling bipolar disorder. Bipolar Disord 2003; 5(suppl 1): 58 (abstract P100).
60. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65:903-907.
61. Zanarini MC, Vujanovic AA, Parachini EA, Boulanger BS, Frankenburg FR, Hennen J. Zanarini Rating Scale for borderline personality disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Personal Disord 2003; 17:233-242.
62. Zanarini MC, Frankenburg FR, Dubo ED, Sickel AE, Trikha A, Levin A, Reynolds V. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998; 155:1733-1739.
63. Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related life style choices, and costly forms of health care utilization. J Clin Psychiatry. 2004; 65:1660-1665.